An autoradiographic evaluation of AV-1451 Tau PET in dementia

Acta Neuropathologica Communications

Volumn 4, Issue 1, 2016, Pages

  Lowe, Val J ^a   Curran, Geoffry ^a   Fang, Ping ^a   Liesinger, Amanda M ^b   Josephs, Keith A ^a   Parisi, Joseph E ^a   Kantarci, Kejal ^a   Boeve, Bradley F ^a   Pandey, Mukesh K ^a   Bruinsma, Tyler ^a   Knopman, David S ^a   Jones, David T ^a   Petrucelli, Leonard ^b   Cook, Casey N ^b   Graff Radford, Neill R ^c   Dickson, Dennis W ^b   Petersen, Ronald C ^a   Jack, Clifford R ^a   Murray, Melissa E ^b  

^a MAYO CLINIC   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

^c MAYO CLINIC   (United States)

Author keywords

Alzheimer's disease; Atypical alzheimer's disease; AV 1451; Corticobasal degeneration; Frontotemporal dementia; Pick disease; Pick's disease; Progressive supranuclear palsy; Tau; Tauopathy; TDP 43

Indexed keywords

7-(6-FLUOROPYRIDIN-3-YL)-5H-PYRIDO(4,3-B)INDOLE; CARBOLINE DERIVATIVE; DNA BINDING PROTEIN; ISOPROTEIN; MAPT PROTEIN, HUMAN; RADIOPHARMACEUTICAL AGENT; TAU PROTEIN; TDP-43 PROTEIN, HUMAN;

AGED; AUTORADIOGRAPHY; BRAIN; DEGENERATIVE DISEASE; DEMENTIA; DIAGNOSTIC IMAGING; EVALUATION STUDY; FEMALE; HUMAN; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; SYNTHESIS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; AUTORADIOGRAPHY; BRAIN; CARBOLINES; DEMENTIA; DNA-BINDING PROTEINS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEURODEGENERATIVE DISEASES; POSITRON-EMISSION TOMOGRAPHY; PROTEIN ISOFORMS; RADIOPHARMACEUTICALS; TAU PROTEINS;

EID: 85007591207     PISSN: None     EISSN: 20515960     Source Type: Journal    
DOI: 10.1186/s40478-016-0315-6     Document Type: Article

References (56)

1. Goedert M, Spillantini MG, Potier MC, Ulrich J, Crowther RA. Cloning and sequencing of the cDNA encoding an isoform of microtubule-associated protein tau containing four tandem repeats: differential expression of tau protein mRNAs in human brain. EMBO J. 1989;8:393-9.
2. Bennett DA, Schneider JA, Wilson RS, Bienias JL, Arnold SE. Neurofibrillary tangles mediate the association of amyloid load with clinical Alzheimer disease and level of cognitive function. Arch Neurol. 2004;61:378-84. doi:10. 1001/archneur.61.3.378.
3. Giannakopoulos P, Herrmann FR, Bussiere T, Bouras C, Kovari E, Perl DP, Morrison JH, Gold G, Hof PR. Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer's disease. Neurology. 2003;60: 1495-500.
4. Janocko NJ, Brodersen KA, Soto-Ortolaza AI, Ross OA, Liesinger AM, Duara R, Graff-Radford NR, Dickson DW, Murray ME. Neuropathologically defined subtypes of Alzheimer's disease differ significantly from neurofibrillary tangle-predominant dementia. Acta Neuropathol. 2012;124:681-92. doi:10. 1007/s00401-012-1044-y.
5. Jellinger KA, Attems J. Neurofibrillary tangle-predominant dementia: comparison with classical Alzheimer disease. Acta Neuropathol. 2007;113: 107-17. doi:10.1007/s00401-006-0156-7.
6. Tolnay M, Clavaguera F. Argyrophilic grain disease: a late-onset dementia with distinctive features among tauopathies. Neuropathology. 2004;24:269-83.
7. Irwin DJ, Brettschneider J, McMillan CT, Cooper F, Olm C, Arnold SE, Van Deerlin VM, Seeley WW, Miller BL, Lee EB et al. Deep Clinical and Neuropathological Phenotyping of Pick's Disease. Ann Neurol 2015. doi: 10.1002/ana.24559
8. Hauw JJ, Daniel SE, Dickson D, Horoupian DS, Jellinger K, Lantos PL, McKee A, Tabaton M, Litvan I. Preliminary NINDS neuropathologic criteria for Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy). Neurology. 1994;44:2015-9.
9. Dickson DW, Bergeron C, Chin SS, Duyckaerts C, Horoupian D, Ikeda K, Jellinger K, Lantos PL, Lippa CF, Mirra SS, et al. Office of rare diseases neuropathologic criteria for corticobasal degeneration. J Neuropathol Exp Neurol. 2002;61:935-46.
10. Andreadis A, Brown WM, Kosik KS. Structure and novel exons of the human tau gene. Biochemistry. 1992;31:10626-33.
11. Murray ME, Kouri N, Lin WL, Jack Jr CR, Dickson DW, Vemuri P. Clinicopathologic assessment and imaging of tauopathies in neurodegenerative dementias. Alzheimers Res Ther. 2014;6:1. doi:10.1186/alzrt231.
12. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, Bergstrom M, Savitcheva I, Huang GF, Estrada S, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol. 2004;55:306-19. doi:10.1002/ana.20009.
13. Jack Jr CR, Wiste HJ, Weigand SD, Knopman DS, Lowe V, Vemuri P, Mielke MM, Jones DT, Senjem ML, Gunter JL, et al. Amyloid-first and neurodegeneration-first profiles characterize incident amyloid PET positivity. Neurology. 2013;81:1732-40. doi:10.1212/01.wnl.0000435556.21319.e4.
14. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack Jr CR, Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7:263-9. doi:10.1016/j.jalz.2011.03.005.
15. Murray ME, Lowe VJ, Graff-Radford NR, Liesinger AM, Cannon A, Przybelski SA, Rawal B, Parisi JE, Petersen RC, Kantarci K, et al. Clinicopathologic and 11CPittsburgh compound B implications of Thal amyloid phase across the Alzheimer's disease spectrum. Brain. 2015;138:1370-81. doi:10.1093/brain/awv050.
16. Nelson PT, Alafuzoff I, Bigio EH, Bouras C, Braak H, Cairns NJ, Castellani RJ, Crain BJ, Davies P, Del Tredici K, et al. Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol. 2012;71:362-81. doi:10.1097/NEN.0b013e31825018f7.
17. Chien DT, Bahri S, Szardenings AK, Walsh JC, Mu F, Su MY, ShankleWR, Elizarov A, Kolb HC. Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. J Alzheimers Dis. 2013;34:457-68. doi:10.3233/JAD-122059.
18. Xia CF, Arteaga J, Chen G, Gangadharmath U, Gomez LF, Kasi D, Lam C, Liang Q, Liu C, Mocharla VP et al. [(18)F]T807, a novel tau positron emission tomography imaging agent for Alzheimer's disease. Alzheimers Dement 2013. Doi 10.1016/j.jalz.2012.11.008
19. Marquie M, Normandin MD, Vanderburg CR, Costantino IM, Bien EA, Rycyna LG, Klunk WE, Mathis CA, Ikonomovic MD, Debnath ML et al. Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue. Ann Neurol 2015. doi: 10.1002/ana.24517
20. Crary JF, Trojanowski JQ, Schneider JA, Abisambra JF, Abner EL, Alafuzoff I, Arnold SE, Attems J, Beach TG, Bigio EH, et al. Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathol. 2014;128:755-66. doi:10.1007/s00401-014-1349-0.
21. Hyman BT, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Carrillo MC, Dickson DW, Duyckaerts C, Frosch MP, Masliah E, et al. National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement. 2012;8:1-13. doi:10.1016/j.jalz.2011.10.007.
22. Montine TJ, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Dickson DW, Duyckaerts C, Frosch MP, Masliah E, Mirra SS, et al. National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. Acta Neuropathol. 2012;123:1-11. doi:10.1007/s00401-011-0910-3.
23. Cairns NJ, Bigio EH, Mackenzie IR, Neumann M, Lee VM, Hatanpaa KJ, White CL, 3rd, Schneider JA, Grinberg LT, Halliday G, et al. Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration. Acta Neuropathol. 2007; 114:5-22. doi:10.1007/s00401-007-0237-2.
24. Rodriguez DR, Grinberg LT. Argryophilic Grain Disease: An Underestimated Tauopathy. Dement Neuropyscol. 2015;9:7.
25. van Swieten JC, Stevens M, Rosso SM, Rizzu P, Joosse M, de Koning I, Kamphorst W, Ravid R, Spillantini MG, Niermeijer et al. Phenotypic variation in hereditary frontotemporal dementia with tau mutations. Annals of neurology 1999; 46: 617-626
26. McKeith IG. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): Report of the Consortium on DLB International Workshop. J Alzheimers Dis. 2006;9:417-23.
27. Gilman S, Wenning GK, Low PA, Brooks DJ, Mathias CJ, Trojanowski JQ, Wood NW, Colosimo C, Durr A, Fowler CJ, et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology. 2008;71: 670-6. doi:10.1212/01.wnl.0000324625.00404.15.
28. Schneider SA, Dusek P, Hardy J, Westenberger A, Jankovic J, Bhatia KP. Genetics and Pathophysiology of Neurodegeneration with Brain Iron Accumulation (NBIA). Curr Neuropharmacol. 2013;11:59-79. doi:10.2174/ 157015913804999469.
29. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82:239-59.
30. Murray ME, Graff-Radford NR, Ross OA, Petersen RC, Duara R, Dickson DW. Neuropathologically defined subtypes of Alzheimer's disease with distinct clinical characteristics: a retrospective study. Lancet Neurol. 2011;10:785-96. doi:10.1016/S1474-4422(11)70156-9.
31. Arvanitakis Z, Witte RJ, Dickson DW, Tsuboi Y, Uitti RJ, Slowinski J, Hutton ML, Lin SC, Boeve BF, Cheshire WP, et al. Clinical-pathologic study of biomarkers in FTDP-17 (PPND family with N279K tau mutation). Parkinsonism Relat Disord. 2007;13:230-9. doi:10.1016/j.parkreldis.2006.10.007.
32. Whitwell JL, Jack Jr CR, Boeve BF, Senjem ML, Baker M, Ivnik RJ, Knopman DS, Wszolek ZK, Petersen RC, Rademakers R, et al. Atrophy patterns in IVS10 + 16, IVS10 + 3, N279K, S305N, P301L, and V337M MAPT mutations. Neurology. 2009;73:1058-65. doi:10.1212/WNL.0b013e3181b9c8b9.
33. Mackenzie IR, Neumann M, Baborie A, Sampathu DM, Du Plessis D, Jaros E, Perry RH, Trojanowski JQ, Mann DM, Lee VM. A harmonized classification system for FTLD-TDP pathology. Acta Neuropathol. 2011;122:111-3. doi:10. 1007/s00401-011-0845-8.
34. Jack Jr CR, Lowe VJ, Weigand SD, Wiste HJ, Senjem ML, Knopman DS, Shiung MM, Gunter JL, Boeve BF, Kemp BJ, et al. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain. 2009;132: 1355-65. doi:10.1093/brain/awp062.
35. Beach TG, White CL, Hamilton RL, Duda JE, Iwatsubo T, Dickson DW, Leverenz JB, Roncaroli F, Buttini M, Hladik CL, et al. Evaluation of alpha-synuclein immunohistochemical methods used by invited experts. Acta Neuropathol. 2008;116:277-88. doi:10.1007/s00401-008-0409-8.
36. Ebrahim AS, Kulathingal J, Murray ME, Casey-Castanedes M, Dickson DW, Yen SH, Sevlever D. A proteomic study identifies different levels of light chain ferritin in corticobasal degeneration and progressive supranuclear palsy. Acta Neuropathol. 2011;122:727-36. doi:10.1007/s00401-011-0888-x.
37. Thal DR, Rub U, Orantes M, Braak H. Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology. 2002;58:1791-800.
38. Xia CF, Arteaga J, Chen G, Gangadharmath U, Gomez LF, Kasi D, Lam C, Liang Q, Liu C, Mocharla VP, et al. [(18)F]T807, a novel tau positron emission tomography imaging agent for Alzheimer's disease. Alzheimers Dement. 2013;9:666-76. doi:10.1016/j.jalz.2012.11.008.
39. Josephs KA, Duffy JR, Strand EA, Whitwell JL, Layton KF, Parisi JE, Hauser MF, Witte RJ, Boeve BF, Knopman DS, et al. Clinicopathological and imaging correlates of progressive aphasia and apraxia of speech. Brain. 2006;129:1385-98. doi:10.1093/brain/awl078.
40. Sander K, Lashley T, Gami P, Gendron T, Lythgoe MF, Rohrer JD, Schott JM, Revesz T, Fox NC, Arstad E. Characterization of tau positron emission tomography tracer [F]AV-1451 binding to postmortem tissue in Alzheimer's disease, primary tauopathies, and other dementias. Alzheimers Dement 2016. doi: 10.1016/j.jalz. 2016.01.003
41. Kimura T, Ono T, Takamatsu J, Yamamoto H, Ikegami K, Kondo A, Hasegawa M, Ihara Y, Miyamoto E, Miyakawa T. Sequential changes of tau-site-specific phosphorylation during development of paired helical filaments. Dementia. 1996;7:177-81.
42. Wischik CM, Novak M, Edwards PC, Klug A, Tichelaar W, Crowther RA. Structural characterization of the core of the paired helical filament of Alzheimer disease. Proc Natl Acad Sci U S A. 1988;85:4884-8.
43. Santa-Maria I, Haggiagi A, Liu X, Wasserscheid J, Nelson PT, Dewar K, Clark LN, Crary JF. The MAPT H1 haplotype is associated with tangle-predominant dementia. Acta Neuropathol. 2012;124:693-704. doi:10.1007/s00401-012-1017-1.
44. Hara M, Hirokawa K, Kamei S, Uchihara T. Isoform transition from fourrepeat to three-repeat tau underlies dendrosomatic and regional progression of neurofibrillary pathology. Acta Neuropathol. 2013;125: 565-79. doi:10.1007/s00401-013-1097-6.
45. Duyckaerts C, Braak H, Brion JP, Buee L, Del Tredici K, Goedert M, Halliday G, Neumann M, Spillantini MG, Tolnay M et al. PART is part of Alzheimer disease. Acta neuropathologica 2015. doi 10.1007/s00401-015-1390-7
46. Jack Jr CR. PART and SNAP. Acta Neuropathol. 2014;128:773-6. doi:10. 1007/s00401-014-1362-3.
47. Braak H, Braak E. On areas of transition between entorhinal allocortex and temporal isocortex in the human brain. Normal morphology and laminaspecific pathology in Alzheimer's disease. Acta Neuropathol. 1985;68:325-32.
48. Gomez-Isla T, Price JL, McKeel Jr DW, Morris JC, Growdon JH, Hyman BT. Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer's disease. J Neurosci. 1996;16:4491-500.
49. Fodero-Tavoletti MT, Furumoto S, Taylor L, McLean CA, Mulligan RS, Birchall I, Harada R, Masters CL, Yanai K, Kudo Y, et al. Assessing THK523 selectivity for tau deposits in Alzheimer's disease and non-Alzheimer's disease tauopathies. Alzheimers Res Ther. 2014;6:11. doi:10.1186/alzrt240.
50. Maruyama M, Shimada H, Suhara T, Shinotoh H, Ji B, Maeda J, Zhang MR, Trojanowski JQ, Lee VM, Ono M, et al. Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls. Neuron. 2013;79:1094-108. doi:10.1016/j.neuron.2013.07.037.
51. Higuchi M, Lee VM, Trojanowski JQ. Tau and axonopathy in neurodegenerative disorders. Neuromolecular Med. 2002;2:131-50. doi:10. 1385/NMM:2:2:131.
52. Graff-Radford J, Josephs KA, Parisi JE, Dickson DW, Giannini C, Boeve BF. Globular Glial Tauopathy Presenting as Semantic Variant Primary Progressive Aphasia. JAMA Neurol. 2016;73:123-5. doi:10.1001/jamaneurol.2015.2711.
53. Hodges JR, Mitchell J, Dawson K, Spillantini MG, Xuereb JH, McMonagle P, Nestor PJ, Patterson K. Semantic dementia: demography, familial factors and survival in a consecutive series of 100 cases. Brain. 2010;133:300-6. doi:10.1093/ brain/awp248.
54. Zecca L, Casella L, Albertini A, Bellei C, Zucca FA, Engelen M, Zadlo A, Szewczyk G, Zareba M, Sarna T. Neuromelanin can protect against ironmediated oxidative damage in system modeling iron overload of brain aging and Parkinson's disease. J Neurochem. 2008;106:1866-75. doi:10.1111/ j.1471-4159.2008.05541.x.
55. Fowler DM, Koulov AV, Alory-Jost C, Marks MS, Balch WE, Kelly JW. Functional amyloid formation within mammalian tissue. PLoS Biol. 2006; 4:e6. doi:10.1371/journal.pbio.0040006.
56. Wen GY, Wisniewski HM, Kascsak RJ. Biondi ring tangles in the choroid plexus of Alzheimer's disease and normal aging brains: a quantitative study. Brain Res. 1999;832:40-6.